zolucatetide + zoldonrasib + cetuximab

zolucatetide + zoldonrasib + cetuximab is an investigational combination regimen consisting of three active agents: zolucatetide (FOG-001), zoldonrasib (RMC-9805), and cetuximab. Zolucatetide is a first-in-class competitive peptide inhibitor of the β-catenin and T-cell factor (TCF) transcription factor interaction, developed using Parabilis Medicines' Helicon platform. Zoldonrasib is an oral, covalent RAS(ON) G12D-selective tri-complex inhibitor developed by Revolution Medicines that acts as a molecular glue to link cyclophilin A to GTP-bound mutant KRAS/RAS G12D. Cetuximab is an approved chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This triple-combination regimen is being evaluated under a clinical collaboration between Parabilis Medicines and Revolution Medicines for the treatment of patients with previously treated RAS G12D-mutant microsatellite-stable (MSS) metastatic colorectal cancer. Preclinical data in patient-derived xenograft models of colorectal cancer have demonstrated enhanced tumor growth inhibition when zolucatetide is combined with zoldonrasib.